Moderna 7. Mai 2026 Moderna’s mRNA flu vaccine more effective than current SOC - Clinical Trials Arena
Moderna 7. Mai 2026 Korea University and Moderna have been working on mRNA hantavirus vaccine since 2023 - Brussels Signal
Moderna 7. Mai 2026 Phase 3 trial finds Moderna mRNA flu vaccine outperforms standard vaccine in older adults - CIDRAP
Moderna 5. Mai 2026 Boston biotech firms back new effort to preserve U.S. edge in life sciences - The Business Journals
Moderna 4. Mai 2026 Vertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues - Fierce Biotech
Moderna 4. Mai 2026 Biopharma bites: Tolerability sinks Vertex-Moderna's CF candidate, Takeda's immune win, and more from Amgen, Latus - FirstWord Pharma
Moderna 1. Mai 2026 Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna 30. Apr. 2026 Moderna loses key mRNA patent in European vaccine fight - Life Sciences Intellectual Property Review
Moderna 28. Apr. 2026 Moderna Deploys Salesforce Agentforce Life Sciences to Unify Global Commercial Operations - HIT Consultant
Moderna 28. Apr. 2026 CureVac targets Moderna with 10-patent suit over Spikevax - Life Sciences Intellectual Property Review
Moderna 22. Apr. 2026 Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - BioPharma Dive
Moderna 22. Apr. 2026 Moderna launches mRNA bird flu vaccine trial after HHS cancels funding - The Washington Post
Moderna 21. Apr. 2026 Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Moderna 20. Apr. 2026 Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNEXSPIKE - Fierce Pharma